Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis
- Author(s)
- Hall, VG; Lim, C; Saunders, NR; Klimevski, E; Nguyen, THO; Kedzierski, L; Seymour, JF; Wadhwa, V; Thursky, KA; Yong, MK; Kedzierska, K; Slavin, MA; Teh, BW;
- Details
- Publication Year 2023-09,Volume 64,Issue #9,Page 1600-1604
- Journal Title
- Leukemia & Lymphoma
- Publication Type
- Research article
- Publisher
- Taylor & Francis
- Keywords
- Humans; *Pre-Exposure Prophylaxis; *COVID-19/prevention & control; Antibodies, Monoclonal
- Department(s)
- Clinical Haematology; Ambulatory Services; Infectious Diseases
- PubMed ID
- 37341732
- Publisher's Version
- https://doi.org/10.1080/10428194.2023.2224472
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-15 06:57:58
Last Modified: 2024-07-09 05:30:59